Illinois Municipal Retirement Fund Makes New $774,000 Investment in Charles River Laboratories International, Inc. $CRL

Illinois Municipal Retirement Fund bought a new position in shares of Charles River Laboratories International, Inc. (NYSE:CRL) in the 1st quarter, according to the company in its most recent disclosure with the SEC. The fund bought 4,485 shares of the medical research company’s stock, valued at approximately $774,000.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Tema Etfs LLC acquired a new position in shares of Charles River Laboratories International in the fourth quarter valued at about $26,000. Los Angeles Capital Management LLC bought a new position in Charles River Laboratories International in the 4th quarter valued at about $42,000. Sfam LLC bought a new position in Charles River Laboratories International in the 4th quarter valued at about $43,000. Activest Wealth Management raised its position in Charles River Laboratories International by 10,900.0% during the fourth quarter. Activest Wealth Management now owns 220 shares of the medical research company’s stock valued at $44,000 after purchasing an additional 218 shares in the last quarter. Finally, Geneos Wealth Management Inc. raised its holdings in shares of Charles River Laboratories International by 98.0% during the 2nd quarter. Geneos Wealth Management Inc. now owns 293 shares of the medical research company’s stock worth $44,000 after buying an additional 145 shares in the last quarter. 98.91% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

CRL has been the subject of a number of research analyst reports. Evercore reiterated an “outperform” rating and set a $220.00 price objective on shares of Charles River Laboratories International in a research report on Friday, May 8th. Sanford C. Bernstein set a $250.00 price objective on Charles River Laboratories International in a research note on Wednesday, July 1st. Weiss Ratings upgraded shares of Charles River Laboratories International from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, July 1st. Mizuho lifted their target price on shares of Charles River Laboratories International from $192.00 to $230.00 and gave the stock a “neutral” rating in a research report on Monday, July 13th. Finally, BNP Paribas Exane set a $250.00 price target on shares of Charles River Laboratories International in a research report on Wednesday, July 1st. Eleven analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $220.75.

Charles River Laboratories International Stock Up 4.7%

Shares of NYSE:CRL opened at $228.99 on Friday. The company has a market capitalization of $11.03 billion, a price-to-earnings ratio of -60.90, a P/E/G ratio of 2.43 and a beta of 1.40. The company has a debt-to-equity ratio of 0.90, a current ratio of 1.36 and a quick ratio of 1.03. The business’s 50-day moving average is $197.28 and its 200-day moving average is $187.23. Charles River Laboratories International, Inc. has a 1 year low of $144.26 and a 1 year high of $238.85.

Charles River Laboratories International (NYSE:CRL) last released its earnings results on Thursday, May 7th. The medical research company reported $2.06 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.96 by $0.10. Charles River Laboratories International had a negative net margin of 4.59% and a positive return on equity of 15.36%. The company had revenue of $995.83 million for the quarter, compared to the consensus estimate of $977.46 million. During the same quarter in the previous year, the company earned $2.34 EPS. Charles River Laboratories International’s quarterly revenue was up 1.2% compared to the same quarter last year. Charles River Laboratories International has set its FY 2026 guidance at 10.800-11.300 EPS. Equities research analysts predict that Charles River Laboratories International, Inc. will post 11.05 earnings per share for the current year.

Insider Activity

In other news, Director James C. Foster sold 75,000 shares of the firm’s stock in a transaction dated Monday, June 29th. The stock was sold at an average price of $225.00, for a total value of $16,875,000.00. Following the completion of the sale, the director directly owned 31,596 shares in the company, valued at $7,109,100. This trade represents a 70.36% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 1.30% of the stock is owned by company insiders.

About Charles River Laboratories International

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.